A global cancer data integrator reveals principles of synthetic lethality, sex disparity and immunotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-994X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A global cancer data integrator reveals principles of synthetic lethality, sex disparity and immunotherapy ; volume:13 ; number:1 ; day:18 ; month:10 ; year:2021 ; pages:1-12 ; date:12.2021
Genome medicine ; 13, Heft 1 (18.10.2021), 1-12, 12.2021
- Creator
-
Yogodzinski, Christopher
Arab, Abolfazl
Pritchard, Justin R.
Goodarzi, Hani
Gilbert, Luke A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13073-021-00987-8
- URN
-
urn:nbn:de:101:1-2022011121070887898841
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yogodzinski, Christopher
- Arab, Abolfazl
- Pritchard, Justin R.
- Goodarzi, Hani
- Gilbert, Luke A.
- SpringerLink (Online service)
Other Objects (12)
Modeling synthetic lethality
Epigenetic synthetic lethality approaches in cancer therapy
Advances in synthetic lethality modalities for glioblastoma multiforme
Telomere dysfunction and synthetic lethality in chronic lymphocytic leukemia
Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
Benchmarking machine learning methods for synthetic lethality prediction in cancer
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality
Synthetic lethality in lung cancer and translation to clinical therapies
Development of synthetic lethality in cancer: molecular and cellular classification
Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
Modeling synthetic lethality
Epigenetic synthetic lethality approaches in cancer therapy
Advances in synthetic lethality modalities for glioblastoma multiforme
Telomere dysfunction and synthetic lethality in chronic lymphocytic leukemia
Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
Benchmarking machine learning methods for synthetic lethality prediction in cancer
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality
Synthetic lethality in lung cancer and translation to clinical therapies
Development of synthetic lethality in cancer: molecular and cellular classification
Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma
Modeling synthetic lethality
Epigenetic synthetic lethality approaches in cancer therapy
Advances in synthetic lethality modalities for glioblastoma multiforme
Telomere dysfunction and synthetic lethality in chronic lymphocytic leukemia
Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
Benchmarking machine learning methods for synthetic lethality prediction in cancer
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality
Synthetic lethality in lung cancer and translation to clinical therapies
Development of synthetic lethality in cancer: molecular and cellular classification